IRADIMED CORP (IRMD) Stock Fundamental Analysis
NASDAQ:IRMD - Nasdaq - US46266A1097 - Common Stock - Currency: USD
IRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. IRMD gets an excellent profitability rating and is at the same time showing great financial health properties. IRMD has a correct valuation and a medium growth rate. These ratings could make IRMD a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year IRMD was profitable.
In the past year IRMD had a positive cash flow from operations.
Each year in the past 5 years IRMD has been profitable.
In the past 5 years IRMD always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of IRMD (19.56%) is better than 97.91% of its industry peers.
The Return On Equity of IRMD (22.15%) is better than 94.76% of its industry peers.
IRMD has a Return On Invested Capital of 19.36%. This is amongst the best in the industry. IRMD outperforms 98.43% of its industry peers.
The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 7.68%.
The last Return On Invested Capital (19.36%) for IRMD is above the 3 year average (18.78%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.56% | ||
| ROE | 22.15% | ||
| ROIC | 19.36% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 26.26%, IRMD belongs to the best of the industry, outperforming 95.81% of the companies in the same industry.
In the last couple of years the Profit Margin of IRMD has remained more or less at the same level.
Looking at the Operating Margin, with a value of 29.99%, IRMD belongs to the top of the industry, outperforming 98.43% of the companies in the same industry.
In the last couple of years the Operating Margin of IRMD has grown nicely.
IRMD's Gross Margin of 76.94% is amongst the best of the industry. IRMD outperforms 90.05% of its industry peers.
In the last couple of years the Gross Margin of IRMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 29.99% | ||
| PM (TTM) | 26.26% | ||
| GM | 76.94% |
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IRMD is creating value.
The number of shares outstanding for IRMD has been increased compared to 1 year ago.
Compared to 5 years ago, IRMD has more shares outstanding
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 36.78 indicates that IRMD is not in any danger for bankruptcy at the moment.
IRMD has a Altman-Z score of 36.78. This is amongst the best in the industry. IRMD outperforms 100.00% of its industry peers.
There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 36.78 |
ROIC/WACC2.13
WACC9.08%
2.3 Liquidity
IRMD has a Current Ratio of 8.84. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 8.84, IRMD belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
IRMD has a Quick Ratio of 7.62. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
IRMD has a Quick ratio of 7.62. This is amongst the best in the industry. IRMD outperforms 90.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.84 | ||
| Quick Ratio | 7.62 |
3. Growth
3.1 Past
IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.49%, which is quite good.
IRMD shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.92% yearly.
Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 11.71% in the last year.
Measured over the past years, IRMD shows a quite strong growth in Revenue. The Revenue has been growing by 13.71% on average per year.
EPS 1Y (TTM)11.49%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%12.82%
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%11.1%
3.2 Future
Based on estimates for the next years, IRMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.61% on average per year.
The Revenue is expected to grow by 13.15% on average over the next years. This is quite good.
EPS Next Y8.18%
EPS Next 2Y11.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.74%
Revenue Next 2Y13.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 30.78, the valuation of IRMD can be described as expensive.
Based on the Price/Earnings ratio, IRMD is valued a bit cheaper than the industry average as 72.25% of the companies are valued more expensively.
IRMD's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.63.
The Price/Forward Earnings ratio is 28.45, which means the current valuation is very expensive for IRMD.
Based on the Price/Forward Earnings ratio, IRMD is valued a bit cheaper than 73.30% of the companies in the same industry.
IRMD's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 20.85.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.78 | ||
| Fwd PE | 28.45 |
4.2 Price Multiples
IRMD's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 70.16% of the companies in the same industry.
IRMD's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 76.44% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 38.43 | ||
| EV/EBITDA | 26.06 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
IRMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)3.76
PEG (5Y)2.21
EPS Next 2Y11.61%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IRMD has a Yearly Dividend Yield of 1.20%. Purely for dividend investing, there may be better candidates out there.
IRMD's Dividend Yield is rather good when compared to the industry average which is at 1.94. IRMD pays more dividend than 94.76% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.51, IRMD's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.2% |
5.2 History
IRMD has paid a dividend for less than 5 years, so there is no long track record yet.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
71.11% of the earnings are spent on dividend by IRMD. This is not a sustainable payout ratio.
DP71.11%
EPS Next 2Y11.61%
EPS Next 3YN/A
50.78
-0.99 (-1.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners58.66%
Inst Owner Change-0.14%
Ins Owners37.05%
Ins Owner Change1%
Market Cap645.92M
Analysts82.5
Price Target72.42 (42.62%)
Short Float %2.53%
Short Ratio4.92
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.2% |
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP71.11%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.77%
Min EPS beat(2)-1.96%
Max EPS beat(2)9.5%
EPS beat(4)3
Avg EPS beat(4)6.43%
Min EPS beat(4)-1.96%
Max EPS beat(4)12.81%
EPS beat(8)6
Avg EPS beat(8)6.97%
EPS beat(12)10
Avg EPS beat(12)7.51%
EPS beat(16)14
Avg EPS beat(16)15.55%
Revenue beat(2)0
Avg Revenue beat(2)-0.71%
Min Revenue beat(2)-0.72%
Max Revenue beat(2)-0.71%
Revenue beat(4)1
Avg Revenue beat(4)-0.28%
Min Revenue beat(4)-0.72%
Max Revenue beat(4)0.72%
Revenue beat(8)4
Avg Revenue beat(8)0.18%
Revenue beat(12)4
Avg Revenue beat(12)-0.25%
Revenue beat(16)8
Avg Revenue beat(16)1.2%
PT rev (1m)0%
PT rev (3m)18.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.55%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 30.78 | ||
| Fwd PE | 28.45 | ||
| P/S | 8.82 | ||
| P/FCF | 38.43 | ||
| P/OCF | 25.21 | ||
| P/B | 7.44 | ||
| P/tB | 7.72 | ||
| EV/EBITDA | 26.06 |
EPS(TTM)1.65
EY3.25%
EPS(NY)1.79
Fwd EY3.52%
FCF(TTM)1.32
FCFY2.6%
OCF(TTM)2.01
OCFY3.97%
SpS5.76
BVpS6.83
TBVpS6.58
PEG (NY)3.76
PEG (5Y)2.21
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 19.56% | ||
| ROE | 22.15% | ||
| ROCE | 24.46% | ||
| ROIC | 19.36% | ||
| ROICexc | 46.27% | ||
| ROICexgc | 50.43% | ||
| OM | 29.99% | ||
| PM (TTM) | 26.26% | ||
| GM | 76.94% | ||
| FCFM | 22.95% |
ROA(3y)17.74%
ROA(5y)13.28%
ROE(3y)21.21%
ROE(5y)15.76%
ROIC(3y)18.78%
ROIC(5y)N/A
ROICexc(3y)57.41%
ROICexc(5y)N/A
ROICexgc(3y)63.62%
ROICexgc(5y)N/A
ROCE(3y)23.73%
ROCE(5y)N/A
ROICexcg growth 3Y-6.9%
ROICexcg growth 5Y0.27%
ROICexc growth 3Y-6.89%
ROICexc growth 5Y-0.24%
OM growth 3Y8.49%
OM growth 5Y5.96%
PM growth 3Y5.58%
PM growth 5Y0.99%
GM growth 3Y0.12%
GM growth 5Y-0.04%
F-Score8
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1078.24% | ||
| Cap/Sales | 12.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 112.47% | ||
| Profit Quality | 87.39% | ||
| Current Ratio | 8.84 | ||
| Quick Ratio | 7.62 | ||
| Altman-Z | 36.78 |
F-Score8
WACC9.08%
ROIC/WACC2.13
Cap/Depr(3y)801.75%
Cap/Depr(5y)501.1%
Cap/Sales(3y)9.26%
Cap/Sales(5y)6.31%
Profit Quality(3y)60.91%
Profit Quality(5y)134.72%
High Growth Momentum
Growth
EPS 1Y (TTM)11.49%
EPS 3Y25.74%
EPS 5Y13.92%
EPS Q2Q%12.82%
EPS Next Y8.18%
EPS Next 2Y11.61%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.71%
Revenue growth 3Y20.55%
Revenue growth 5Y13.71%
Sales Q2Q%11.1%
Revenue Next Year8.74%
Revenue Next 2Y13.15%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.61%
EBIT growth 3Y30.78%
EBIT growth 5Y20.49%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y207.96%
FCF growth 3Y16.9%
FCF growth 5Y11.53%
OCF growth 1Y90.3%
OCF growth 3Y31.53%
OCF growth 5Y20.16%